Shweta Maniar
Known title: DirectorCIK: 0001850826
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| OFIX | ▲ Buy | Grant | 14,965 | $0 | 6/10/2026 | View on chart |
| OFIX | ▲ Buy | Grant | 18,841 | $0 | 6/18/2025 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| RXST | ▼ Sell | Open Market | 3,519 | $109K | 1/22/2025 | View on chart |
| RXST | ▼ Sell | Open Market | 3,782 | $174K | 11/26/2024 | View on chart |
| OFIX | ▲ Buy | Grant | 15,152 | $195K | 6/18/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 3,520 | $161K | 1/18/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 2,879 | $132K | 1/18/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 6,418 | $289K | 1/8/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 4,292 | $120K | 8/29/2023 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| OFIX | ▼ Sell | Open Market | 4,262 | $76K | 3/10/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,052 | $0 | 1/5/2023 | View on chart |
| RXST | ▲ Buy | Grant | 4,312 | $0 | 6/2/2022 | View on chart |
| RXST | ▲ Buy | Grant | 19,196 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.